Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juergen M. Schanzer"'
Publikováno v:
Journal of Immunotherapy. 29:477-488
Cytokine targeting to tumor-associated antigens via antibody cytokine fusion proteins has demonstrated potent antitumor activity in numerous animal models and has led to the clinical development of 2 antibody-interleukin-2 (IL-2) fusion proteins. We
Autor:
and Juergen M. Schanzer, James B. Wiesner, Jay DaRe, Joseph J. Kopcho, Mark D. Erion, Angelo J. Castellino, Bheemarao G. Ugarkar
Publikováno v:
Journal of Medicinal Chemistry. 43:2883-2893
Adenosine receptor agonists produce a wide variety of therapeutically useful pharmacologies. However, to date they have failed to undergo successful clinical development due to dose-limiting side effects. Adenosine kinase inhibitors (AKIs) represent
Publikováno v:
Cancer immunity. 6
Pro-inflammatory cytokines regulate the growth, differentiation, and activation of immune cells and can play a role in antitumor responses. GM-CSF and IL-2 induce tumor rejection in animal models when expressed by tumor cells, and IL-2 is used for th
Autor:
Bheemarao G. Ugarkar, Angelo J. Castellino, Jay M. DaRe, Joseph J. Kopcho, James B. Wiesner, Juergen M. Schanzer, Mark D. Erion
Publikováno v:
Journal of medicinal chemistry. 43(15)
In the preceding article (Ugarkar et al. J. Med. Chem. 2000, 43) we reported that analogues of tubercidin are potent adenosine kinase (AK) inhibitors with antiseizure activity in the rat maximum electroshock (MES) model. Despite the discovery of seve